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Abstract
Introduction: Early identification of septic patients at high risk of dying remains a challenge. The prognostic role
of brain natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) in septic patients
remains controversial. The purpose of this systematic review and meta-analysis was to investigate the value of
elevated BNP or NT-proBNP in predicting mortality in septic patients.
Methods: PubMed, Embase and the Cochrane Central Register of Controlled Trials were searched (up to February
18, 2011). Studies were included if they had prospectively collected data on all-cause mortality in adult septic
patients with either plasma BNP or NT-proBNP measurement. Studies that failed to construct a 2 × 2 table of
results were excluded. Two authors independently determined the validity of included studies and extracted data.
Results: 12 studies with a total of 1,865 patients were included. Elevated natriuretic peptides were significantly
associated with increased risk of mortality (odds ratio (OR) 8.65, 95% confidence interval (CI) 4.94 to 15.13, P <
0.00001). The association was consistent for BNP (OR 10.44, 95% CI 4.99 to 21.58, P < 0.00001) and NT-proBNP (OR
6.62, 95% CI 2.68 to 16.34, P < 0.0001). The pooled sensitivity, specificity, positive likelihood ratio, and negative
likelihood ratio were 79% (95% CI 75 to 83), 60% (95% CI 57 to 62), 2.27 (95% CI 1.83 to 2.81) and 0.32 (95% CI 0.22
to 0.46), respectively.
Conclusions: Our results suggested that an elevated BNP or NT-proBNP level may prove to be a powerful
predictor of mortality in septic patients. Future larger and more adequately powered prospective studies are
warranted to clarify the assay standardization, the optimal cut-off, and the prognostic value of BNPs in conjunction
with other biomarkers.
Introduction
Sepsis is a leading cause of death in critically ill patients
despite improvements in antimicrobial therapy and sup-
portive care [1]. The septic response is an extremely
complex chain of events involving inflammatory and
anti-inflammatory processes, hormonal and cellular
reactions, and circulatory abnormalities [2,3]. Early iden-
tification of patients at high risk of dying after intensive
care unit (ICU) admission may help determine thera-
peutic interventions, such as changes in therapeutic
protocols or further diagnostic procedures aiming at
preventing shock and multiple organ failure with all
their sequels that could have an impact on patients’ out-
come [4-6]. Therefore, there is a need for a fast simple
and cost-effective method to enhance risk stratification
in septic patients.
Brian natriuretic peptide (BNP) and its inactive cleavage
product N-terminal fragment (NT-proBNP) were secreted
into the blood in response to atrial or ventricular wall
stretch [7], or myocardial ischemia [8] by cardiomyocytes.
The half-life of BNP is approximately 20 minutes, and that
of NT-proBNP is 1-2 hours [9]. The term BNPs will be
used to represent either BNP or NT-proBNP throughout
the rest of the paper unless otherwise stated.
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BNPs have been found to be useful markers in the
diagnosis, management and prognosis of patients with
congestive heart failure [10]. In addition, BNPs are
powerful predictors of death and major adverse cardio-
vascular events in patients with stable coronary disease
[11], acute coronary syndromes [12] and pulmonary
embolism, [13] and those who undergo noncardiac sur-
gery [14]. Several prospective studies have been per-
formed to investigate the potential role of BNPs in
predicting mortality in septic patients, but they had lim-
ited numbers of patients, used different cut-off points
and involved different clinical endpoints. In the present
study, we made a systematic review and meta-analysis to
evaluate the correlation between elevated levels of BNPs
and death in septic patients.
Materials and methods
This systematic review and meta-analysis was performed
according to the guidelines of Meta-analysis of Observa-
tional Studies in Epidemiology [15].
Study outcome
The aim of this meta-analysis was to see whether ele-
vated BNPs could predict all-cause mortality in adult
patients with sepsis.
Search strategy and eligibility assessment
Pubmed, Embase and the Cochrane Central Register of
Controlled Trials (up to February 18, 2011) were
searched by using Exploded Medical Subject Headings
and the appropriate corresponding keywords, “Brain
natriuretic peptide”, “B-type natriuretic peptide”, “BNP”,
“pro-brain natriuretic peptide”, “amino terminal pro-
brain natriuretic peptide”, “amino terminal pro-BNP”,
“N-terminal pro B-type natriuretic peptide”, “NT-
proBNP”, “natriuretic peptide” AND “sepsis”, “septice-
mia”, “septicaemia”, “septic”. No language restrictions
were applied. Additionally, the reference lists of the ori-
ginal studies and previous review articles were hand-
searched to identify other potentially eligible studies.
Two authors independently determined the eligibility
of all studies identified in initial research. Studies were
included if they prospectively collected data on all-cause
mortality in adult septic patients with either plasma BNP
or NT-proBNP measurement. Studies where a 2 × 2 table
of results could not be constructed were excluded. In
case of disagreements, a third author was consulted.
Agreement regarding study inclusion was assessed using
the Cohen К statistic [16].
Data extraction and quality assessment
Two authors independently extracted the following
descriptive data from all eligible studies: study design,
sample size, patient population, inclusion/exclusion
criteria, diagnostic criteria for sepsis, severe sepsis and
septic shock, follow-up period, completeness of follow-
up, outcome assessment, marker evaluated (i.e., BNP or
NT-proBNP), assay manufacturer, the optimal cut-off
point, timing of BNP measurement, and the proportion
of patients with an elevated BNP measurement. If data
needed clarification or were not presented in the publi-
cation, the original authors were contacted by E-mail.
Extracted data were entered into Microsoft Office Excel
2007 and checked by the third author. Any disagree-
ment was solved by discussion.
Given that the eligible studies were of a prognostic
nature, methodological and reporting quality was
assessed according to the Quality Assessment of Diag-
nostic Accuracy Studies checklist (see Additional file 1)
[17].
Statistical analysis
Results were analyzed using Review Manager 5.1
(Cochrane Collaboration, Oxford, UK) and Meta-Disc 1.4
[18] (Clinical Biostatistics, Ramon y Cajal Hospital,
Madrid, Spain). As individual studies used different cut-
off points for defining elevated BNPs, Spearman’s corre-
lation coefficient between sensitivity and specificity was
calculated to detect the presence of a threshold effect,
where variations in sensitivity and specificity were related
to differences in the cut-off point used to define an ele-
vated BNPs level [19]. If there was no evidence of a
threshold effect, then summary estimates, including odds
ratio (OR), sensitivity, specificity, positive likelihood ratio,
and negative likelihood ratio, were calculated using the
random-effects model based on DerSimonian and Lair’s
meta-analytic statistical method [20]. In case a study pro-
vided multiple cut-off points for BNPs analysis, the point
giving the maximum overall accuracy was chosen. In the
case of analyses with empty cells, 0.5 was added to all
cells to avoid computational errors. Publication bias was
assessed by visually inspecting funnel plot. A p value of
less than 0.05 was considered statistically significant.
Cochrane’s Chi2 test and I2 test for heterogeneity were
used to assess inter-study heterogeneity [21]. The Chi2
test assesses whether observed differences in results are
compatible with chance alone and the I2 describes the
percentage of the variability in effect estimates that is due
to heterogeneity rather than sampling error. Statistically
significant heterogeneity was considered present at Chi2
P < 0.10 and I2 > 50%. To explore the heterogeneity
observed, sensitivity analyses were performed by sequen-
tial exclusion of each study. A prior subgroup analyses to
explain significant heterogeneity were: 1) BNPs type
(BNP versus NT-proBNP); and 2) blinding of BNPs mea-
surement to the outcome (yes versus no). Single covariate
random-effects meta-regression (inverse variance
weights) was also used to explore sources of variation.
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Patient population (sepsis versus severe sepsis or septic
shock), the underlying diseases (inclusion versus exclu-
sion of preexisting conditions known to increase BNPs
levels), optimal timing of BNPs measurement, and mor-
tality were considered as variables.
Results
Our initial search yielded 484 citations, of which 464
were eliminated for various reasons based on the title
and abstract. The full texts of the remaining 20 articles
were scrutinized for further evaluation. Twelve studies
[22-33] fulfilled our eligibility criteria and were finally
included (Figure 1). The Cohen statistic К for agreement
on study inclusion was 0.90.
Characteristics of included studies
The included studies were published from 2004 to 2011
and all were prospective cohort studies (Table 1). Among
them, seven studies [26-29,31-33] were conducted in
Europe, three [24,25,30] in Asia, one [22] in North Amer-
ica, and one [23] in Australasia. Two studies [22,28] were
multicenter studies and one study [23] reported both BNP
and NT-proBNP. All studies but one [24] were published
in English. The mean age of the patients varied between
55 and 69 years and the proportion of men ranged from
47 to 82%. The subject population varied across studies:
three [22,25,26] included patients with sepsis, and nine
[23,24,27-33] with severe sepsis or septic shock. The
selected studies were performed in various departments,
including emergency department, medical ICU, surgical
ICU and general ICU. Nine studies [22,24,26,27,29-33]
excluded patients with preexisting conditions known to
increase BNPs levels. Follow-up periods differed across
studies, including 28 days, ICU stay and hospital stay.
BNPs measurements
Among the included studies, BNP measurement was per-
formed in eight [22-27,30,33] and NT-proBNP in five
[23,28,29,31,32] (Table 2). In the BNP studies, four
[22,23,25,27] used immunoﬂuorescence assay of Triage
BNP test (Biosite Diagnostics, San Diego, CA), three
[26,30,33] utilized immunoradiometric assay (Shionora-
BNP), and one [24] did not report the method of BNP
assay. In the NT-proBNP studies, four [23,28,29,31] used
an electrochemiluminescence immunoassay performed on
a Roche analyzer (Roche Diagnostics), and one study [32]
utilized an enzyme immunoassay (Biozol). Among the
included studies, receiver operating characteristic (ROC)
curve was performed to retrospectively determine the
optimal cut-off point with regard to 28-day mortality in
seven studies [24-27,30,32,33], ICU mortality in two stu-
dies [29,31], in-hospital mortality in two study [23,28], and
a composite outcome of in-hospital mortality, severe sep-
sis, or septic shock in one study [22]. Normal BNPs levels
were defined as levels beneath or equal to the optimal cut-
off points. The optimal cut-off points varied greatly across
studies, from 32.1 pg/ml to 681.4 pg/ml for BNP, and
from 400 pg/ml to 13,600 pg/ml for NT-proBNP. There
were wide variations about the optimal timing of BNP
measurement (six studies [22,24-26,28,31]: the day on
admission; five studies [23,29,30,32,33]: day 2 after admis-
sion; one study [27]: day 5 after admission).
Study quality and publication bias
All the twelve included studies fulfilled the requirements
of a representative spectrum of patients, and clearly
described selection criteria, outcome verification in the
whole cohort, equal outcome evaluation regardless of the
BNPs results, sufficient description of BNPs measurement
for replication and availability of clinical data. Four studies
[22,28,30,33] stated that the BNPs results were interpreted
without knowledge of outcome assessment. Because the
target condition was mortality, outcome assessment was
unlikely to be influenced by knowledge of the BNPs
results. No patient was lost to follow-up.
Regarding the predictive value of elevated BNPs for
mortality, there was no evidence of significant publica-
tion bias by inspection of the funnel plot (Figure 2).
Predictive value of BNPs on all-cause mortality
Overall, 349 (37.6%) of the 929 patients with elevated
BNPs died vs 90 (9.4%) of the 957 patients with normal
BNPs. Spearman’s correlation coefficient between sensitiv-
ity and specificity was -0.132 (P = 0.667), suggesting no
evidence of a threshold effect. Therefore, pooled estimates
were calculated. Elevated BNPs were associated with a sig-
nificantly increased risk of all-cause mortality (OR 8.65,
95% confidence interval (CI) 4.94 to 15.13, P < 0.00001,
Figure 3) with significant heterogeneity (I2 = 64%, P =
0.001). The pooled sensitivity and specificity were 79%
(95% CI 75 to 83, Figure 4) and 60% (95% CI 57 to 62,
Figure 5), respectively. The summary positive and negative
likelihood ratios were 2.27 (95% CI 1.83 to 2.81, Figure 6)
and 0.32 (95% CI 0.22 to 0.46, Figure 7), respectively.
The prior sensitivity analysis suggested that the hetero-
geneity was accounted for by two studies which had the
minimum [28] and maximum [26] areas under the ROC
curve. With the two studies excluded, the pooled OR was
not significantly altered (OR 8.67, 95% CI 5.46 to 13.77,
P < 0.00001) with no significant heterogeneity (I2 = 33%,
P = 0.13). Subgroup analyses suggested that the associa-
tion between elevated BNPs and increased risk of all-cause
mortality was consistent for BNP (OR 10.44, 95% CI 4.99
to 21.58, P < 0.00001; I2 = 64%) [22-27,30,33] and NT-
proBNP (OR 6.62, 95% CI 2.68 to 16.34, P < 0.0001; I2 =
57%) [23,28,29,31,32], as well as blinding (OR 3.83, 95% CI
2.52 to 5.82, P < 0.00001; I2 = 0%) [22,28,30,33] and no
blinding (OR 14.24, 95% CI 6.56 to 30.93, P < 0.00001;
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I2 = 63%) [23-27,29,31,32] of BNPs measurement to the
outcome. According to our priori hypothesis, meta-regres-
sion analyses showed that patient population (P = 0.76),
the underlying diseases (P = 0.12), optimal timing of BNPs
measurement (P = 0.89), and mortality (P = 0.10) did not
explain the demonstrated heterogeneity, respectively.
Discussion
The present meta-analysis showed that elevated BNPs
were associated with a significantly increased risk of mor-
tality in patients with sepsis. The finding is consistent for
both BNP and NT-proBNP. As such, measurement of
BNPs may be a simple method of risk stratification in
septic patients.
BNPs elevation in patients with sepsis can be consid-
erably high, even though cardiac depression is not
obvious. A retrospective study [34] suggested that BNPs
level in septic patients with preserved systolic left ventri-
cular function could be as high as that in patients
admitted to the hospital with congestive heart failure
because of severely impaired systolic left ventricular
function. Aside from neurohormonal activation, several
Figure 1 Flow-chart of study selection.
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Table 1 Characteristics of included studies
Marker Study Country Setting Population NO. Male
(%)




Varpula 2007 [28] Finland 24 ICUs Severe sepsis or septic shock 254 69 59 ± 15 In-hospital mortality 26
Mokart 2007 [29] France ICU Cancer patients developing septic
shock
51 63 56 (50 -
68)†
ICU mortality 51
Roch 2005 [31] France General ICU Septic shock 39 82.1 63 ± 12 ICU mortality 56
Brueckmann 2005
[32]
Germany Three departments in one hospital‡ Severe sepsis 57 74 55.0 ± 16.3 28-day mortality 28
Sturgess 2010b*
[23]
Australia ICU Septic shock 21 61.9 65 ± 17 In-hospital mortality 29
BNP Perman 2011 [22] USA Emergency departments of 10 centers Clinical evidence of sepsis 825 49 53.5 ± 19.6 A composite of
events §
6.6
Zhao 2009 [24] China Surgical ICU Severe sepsis or septic shock 102 53.9 ─ 28-day mortality 38.2
Chen 2009 [25] China Emergency department Sepsis 327 60.6 69.5 ± 13.4 28-day mortality 37.3
Yucel 2008 [26] Turkey General ICU Sepsis 40 ─ ─ 28-day mortality 50
Post 2008 [27] Germany ICU Septic shock 93 55 65(53 -
73.5)†
30-day mortality 40.9
Ueda 2006 [30] Japan Department of Emergency and Critical Care
Medicine
Septic shock 22 77.3 62.5 ± 19.3 28-day mortality 54.5
Charpentier 2004
[33]
France Medical ICU Severe sepsis or septic shock 34 47.1 56 ± 15.7 28-day mortality 29
Sturgess 2010a*
[23]
Australia ICU Septic shock 21 61.9 65 ± 17 In-hospital mortality 29
BNP = brain natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide, ICU = intensive care unit. *The study reported both BNP (Sturgess 2010a) and NT-proBNP (Sturgess 2010b). † Median (25th -
75th percentiles). ¶ Dash indicates that information was not provided. § Events include in-hospital mortality, severe sepsis, or septic shock within 30 days following presentation. ‡ Anesthesiology Department,













mechanisms are likely to account for increased BNPs
levels in sepsis, including sepsis-induced biventricular
dilatation [35], the stimulation of lipopolysaccharide [36]
or proinflammatory cytokines [37,38], volume resuscita-
tion [39] and sepsis-associated acute lung injury or
acute respiratory distress syndrome [40]. Accordingly,
elevated BNPs level in the presence of sepsis does not
essentially mean cardiac dysfunction due to low specifi-
city, while normal BNPs level could be used to rule out
the need for further cardiac investigation, unless there
are other clinical grounds that strongly suspect a signifi-
cant cardiac disorder.
Clinical severity scores such as acute physiology and
chronic health evaluation (APACHE) II and sequential
organ failure assessment (SOFA) scores have been vali-
dated for mortality risk stratification, but are unwieldy
and tend to be used more for audit and research than
clinical decision making in sepsis. A rapidly available bio-
chemical test that provides similar or better prognostic
information could therefore be useful, e.g. to help discus-
sions about prognosis with patients’ relatives and deci-
sions regarding earlier interventions. Several studies
[25,41,42] showed that BNPs level was related to
APACHE II and SOFA scores. In the present meta-analy-
sis, two [25,27] of the included studies directly compared
the prognostic value of BNPs measurement vs clinical
severity scores and both suggested a better prognostic
value of elevated BNPs in predicting mortality. Chen et al
[25] reported a greater area under the ROC curve for the
plasma BNP level than for APACHE Ⅱ score (0.737 vs
0.664). Post et al [27] reported that regarding predicting
Table 2 NT-proBNP and BNP measurements













On admission 7090 58/66 0.631 40.6
Mokart 2007 [29] Roche, Elecsys 2010
analyzer
Day 2 after admission 6624 86/77 0.87 54.9
Roch 2005 [31] Roche, Elecsys 2010
analyzer
Within 24 hours after
admission










Within 72 hours after
admission
400 83/40 0.67 66.7
BNP Perman 2011
[22]
Biosite Diagnostics, Triage On admission 49 63/69 0.69 47.6




681.4 91.4/80.3 0.915 47.1
Chen 2009 [25] Biosite Diagnostics, Triage Within 24 hours after
admission
113 86/55 0.737 32.1
Yucel 2008 [26] Immunoradiometric assay,
Shionoria
On admission 32.1 100/95 0.99 52.5
Post 2008 [27] Biosite Diagnostics, Triage Day 5 after admission 121 76.3/52.7 0.648 59.1
Ueda 2006 [30] Immunoradiometric assay,
Shionoria





Day 2 after admission 190 70/67 0.66 44.1
Sturgess 2010a*
[23]
Biosite Diagnostics, Triage Within 72 hours after
admission
254 83/60 0.76 52.4
BNP = brain natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide. *The study reported both BNP (Sturgess 2010a) and NT-proBNP (Sturgess
2010b). † Manufacture and kind of assay. ‡The manufacture was not reported. ¶ AUC indicates the area under the receiver operating characteristic curve.
Figure 2 Funnel plot for the predictive value of elevated BNP
or NT-proBNP for mortality in patients with sepsis. BNP = brain
natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic
peptide.
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30-day mortality, the area under the ROC curve was
greater for BNP than that for APACHE Ⅱ score and
SOFA score (0.648 vs 0.494 and 0.493, respectively). Con-
sidering the low sensitivity and high specificity of clinical
severity scores, they can be combined with BNPs for
aggregate analysis on the septic prognosis. What addi-
tional value of BNP brings to severity scores on sepsis
risk stratification remains to be determined in further
studies.
As a risk stratification tool, BNPs measurement is sim-
ple, inexpensive, reproducible, non-invasive, and widely
available. These attributes make it highly suitable for
serial testing to monitoring outcome risk over time,
which may be superior to a single value of BNPs
assessed on admission, because dynamic changes in
BNPs concentration may reflect the development of sep-
sis. Furthermore, rather than necessarily dichotomizing
risk as high or low, BNPs express risk as a continuum
and this may be advantageous.
To date, several biomarkers have been identified to
have some prognostic value in the field of sepsis.
According to a prospective multicenter observational
study [43] procalcitonin > 0.85 ng/ml was associated
with an increased risk of death in a Cox regression ana-
lysis (hazard ratio 2.31, 95% CI 1.32-4.05, P = 0.003). In
addition, both elevated cardiac troponin-T [44] and -I
[45] were reported to be associated with higher mortal-
ity in septic patients. In the present study, pooled sensi-
tivity and specificity of elevated BNPs for predicting
mortality in septic patients were 79% and 60%, respec-
tively. So far, none of the proposed prognostic markers
had sufficient (more than 90%) sensitivity and specificity
to predict which patients were at greater risk of dying
due to sepsis [46]. Accordingly, a BNPs measurement
may provide a better prognostic value in combination
with other biomarkers, each mirroring different patho-
physiological aspects. Further study was warranted to
verify this hypothesis and evaluate the cost-effectiveness
in sepsis.
In the past decade, several fully automated, rapid
assays for determination of BNPs have become commer-
cially available, including both high-throughput auto-
mated platforms and point of care tests. Although these
existing BNPs assays correlate closely, BNPs assays are
not currently analytical equivalent due to the lack of
assay standardization [47]. Recently, a multicenter study
Figure 3 Summary of odds ratio of mortality in septic patients with elevated BNP or NT-proBNP. BNP = brain natriuretic peptide, NT-
proBNP = N-terminal pro-B-type natriuretic peptide.
Wang et al. Critical Care 2012, 16:R74
http://ccforum.com/content/16/3/R74
Page 7 of 12
Figure 4 Summary of sensitivity of elevated BNP or NT-proBNP in predicting mortality. BNP = brain natriuretic peptide, NT-proBNP = N-
terminal pro-B-type natriuretic peptide.
Figure 5 Summary of specificity of elevated BNP or NT-proBNP in predicting mortality. BNP = brain natriuretic peptide, NT-proBNP = N-
terminal pro-B-type natriuretic peptide.
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Figure 6 Summary of the positive likelihood ratio of elevated BNP or NT-proBNP in predicting mortality. BNP = brain natriuretic peptide,
NT-proBNP = N-terminal pro-B-type natriuretic peptide.
Figure 7 Summary of the negative likelihood ratio of elevated BNP or NT-proBNP in predicting mortality. BNP = brain natriuretic
peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide.
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conducted in 90 Italian laboratories demonstrated that
there were significant differences in analytical character-
istics and measured values among the most popular
commercial methods for BNP and NT-proBNP [48].
Therefore, clinicians should be very careful when com-
paring results obtained by laboratories that use different
methods.
An important concern of using BNPs in septic
patients is the impact of renal insufficiency on these
tests. Acute renal insufficiency occurs in 11 - 16% of cri-
tically ill patients who presented with sepsis [49,50]. A
study by Goei et al [51] suggested that NT-proBNP had
more favorable discriminative value in patients with a
glomerular filtration rate more than 90 mL/min/1.73
m2, while it lost its prognostic value in patients with a
glomerular filtration rate less than 30 mL/min/1.73 m2.
No guidance on how BNPs values are adjusted for renal
dysfunction is available today. Given the high prevalence
and the impact of renal impairment on the BNPs values,
it is preferable to adopt different cut-offs stratified by
renal function in patients with sepsis.
There were several limitations in the present study.
First, marked heterogeneity existed across the included
studies in terms of population characteristics, BNPs
assays, optimal cut-off point, follow-up period and defi-
nitions of endpoints. However, all the individual ORs
favored the prognostic value of elevated BNPs in pre-
dicting mortality, indicating that the heterogeneity was
entirely quantitative. Although there was uncertainty
regarding the strength of the association, current evi-
dence suggested that there was a significant correlation
between an elevated BNPs level and an increased risk of
mortality in septic patients. Second, the optimal timing
of BNPs measurement varied across the studies, includ-
ing the day on admission, and day 2 and day 5 after
admission. It can be partly accounted for by the diffi-
culty in determining the time of onset of sepsis and,
hence, the time of patient recruitment. Third, it should
be noted that the pooled estimates reflected unadjusted
associations between BNPs and all-cause mortality. Five
[22,25,27,29,31] of the included studies provided
adjusted ORs accounting for confounders. Pooled analy-
sis of the adjusted ORs also suggested that elevated
BNPs were correlated with a significantly increased risk
of mortality in septic patients (random-effects model,
OR 1.87, 95% CI 1.30 to 2.69, P = 0.001). Because the
ORs in the five studies were adjusted by different con-
founders with different regression models and the data
reported on adjusted ORs were limited, we thus adopted
unadjusted mortality data for pooled analyses in the pre-
sent study. Finally, we could not determine the ideal
cutoff points for BNP and NT-proBNP tests because we
did not have the raw data to map out ROC curves. To
determine whether there is a single threshold or a few
important BNP or NT-proBNP thresholds (e.g., age
dependent), further evaluation in prespecified groups of
larger numbers of patients is needed.
Conclusions
This systematic review and meta-analysis suggests that
an elevated BNP or NT-proBNP level may prove to be a
powerful predictor of mortality in patients with sepsis.
This test appears to represent a rapid and relatively
inexpensive method to enhance mortality prediction in
sepsis. Future larger and more adequately powered pro-
spective studies are warranted to clarify the assay stan-
dardization, the optimal cut-off, and the prognostic
value of BNPs in conjunction with other biomarkers.
Key messages
• The literature shows that an elevated BNP or NT-
proBNP level is a powerful predictor of mortality in
patients with sepsis.
• This test appears to represent a rapid and relatively
inexpensive method to enhance mortality prediction
in sepsis.
• Larger adequately powered prospective studies are
warranted to clarify the assay standardization, the
optimal cut-off, and the prognostic value of BNPs in
conjunction with other biomarkers in future.
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